Cover Image
市場調查報告書

抗藥性金黃色葡萄球菌 (MRSA) 感染疾病:全球臨床實驗趨勢

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Global Clinical Trials Review, H2, 2016

出版商 GlobalData 商品編碼 226855
出版日期 內容資訊 英文 177 Pages
訂單完成後即時交付
價格
Back to Top
抗藥性金黃色葡萄球菌 (MRSA) 感染疾病:全球臨床實驗趨勢 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Global Clinical Trials Review, H2, 2016
出版日期: 2016年12月27日 內容資訊: 英文 177 Pages
簡介

本報告提供抗藥性金黃色葡萄球菌 (MRSA) 感染疾病治療藥臨床實驗相關之最新趨勢分析,為您彙整各地區的臨床實驗數量,臨床實驗的各階段進展,實驗對象採用狀況,有潛力的贊助商,各企業和研究機關的研究進展,有潛力的藥劑比較等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲主要國家的臨床實驗數量
    • 中南美主要5國臨床實驗數量

G7各國臨床實驗數量:感染疾病治療藥臨床實驗上抗藥性金黃色葡萄球菌 (MRSA) 感染疾病的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:感染疾病治療藥臨床實驗上抗藥性金黃色葡萄球菌 (MRSA) 感染疾病的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

一定期間所採用的實驗對象

贊助商類別臨床實驗數量

有潛力的贊助商

抗藥性金黃色葡萄球菌 (MRSA) 感染疾病治療藥臨床實驗參與的主要企業

有潛力的藥劑

最新臨床實驗新聞

臨床實驗簡介概要

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4056CTIDB

GlobalData's clinical trial report, "Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Global Clinical Trials Review, H2, 2016" provides an overview of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Methicillin-Resistant Staphylococcus aureus (MRSA) Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
      • Dec 08, 2016: Citius Moves Forward with Mino-Lok Phase 3 Trial
      • Nov 29, 2016: MicuRx Initiates Phase 1 Clinical Trial in U.S. for Novel Antibiotic Agent MRX-4
      • Nov 08, 2016: HKU Chemists achieve breakthrough in antibacterial drug research
      • Oct 26, 2016: Tetraphase Pharmaceuticals Announces Eight Data Presentations at IDWeek 2016
      • Oct 20, 2016: MicuRx Initiates Phase 3 Clinical Trial for MRX-I, A New Potent Oral Antibiotic Against Gram-positive Bacteria, Including MRSA
      • Oct 18, 2016: Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV (telavancin), Including Ongoing TOUR Observational Patient Registry, at IDWeek 2016
      • Oct 04, 2016: Online Media Group covers Phase 3 clinical Trial
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
  • Source

List of Tables

  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Region, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
  • Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
  • Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top